CN1365286A - 治疗慢性乙型肝炎病毒感染的方法 - Google Patents

治疗慢性乙型肝炎病毒感染的方法 Download PDF

Info

Publication number
CN1365286A
CN1365286A CN00810900A CN00810900A CN1365286A CN 1365286 A CN1365286 A CN 1365286A CN 00810900 A CN00810900 A CN 00810900A CN 00810900 A CN00810900 A CN 00810900A CN 1365286 A CN1365286 A CN 1365286A
Authority
CN
China
Prior art keywords
pres2
antigen
hbv
lamivudine
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00810900A
Other languages
English (en)
Chinese (zh)
Inventor
H·赫苏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CN1365286A publication Critical patent/CN1365286A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN00810900A 1999-06-22 2000-06-22 治疗慢性乙型肝炎病毒感染的方法 Pending CN1365286A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14050899P 1999-06-22 1999-06-22
US60/140,508 1999-06-22

Publications (1)

Publication Number Publication Date
CN1365286A true CN1365286A (zh) 2002-08-21

Family

ID=22491558

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00810900A Pending CN1365286A (zh) 1999-06-22 2000-06-22 治疗慢性乙型肝炎病毒感染的方法

Country Status (7)

Country Link
EP (1) EP1189633A2 (pt)
JP (1) JP2003502384A (pt)
KR (1) KR20020020748A (pt)
CN (1) CN1365286A (pt)
AU (1) AU5885700A (pt)
BR (1) BR0011908A (pt)
WO (1) WO2000078343A2 (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104126124A (zh) * 2012-02-20 2014-10-29 弗·哈夫曼-拉罗切有限公司 用于慢性hbv患者的反应预测和疗法监测的hbv免疫复合物
CN116568309A (zh) * 2020-11-18 2023-08-08 株式会社车疫苗研究所 用于预防或治疗慢性乙型肝炎的、包含作为活性成分的口服抗病毒药物和含脂肽和聚(i：c)佐剂的治疗性疫苗的药物组合物、药物组合制剂和组合制剂试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69815692T2 (de) * 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104126124A (zh) * 2012-02-20 2014-10-29 弗·哈夫曼-拉罗切有限公司 用于慢性hbv患者的反应预测和疗法监测的hbv免疫复合物
CN116568309A (zh) * 2020-11-18 2023-08-08 株式会社车疫苗研究所 用于预防或治疗慢性乙型肝炎的、包含作为活性成分的口服抗病毒药物和含脂肽和聚(i：c)佐剂的治疗性疫苗的药物组合物、药物组合制剂和组合制剂试剂盒

Also Published As

Publication number Publication date
WO2000078343A2 (en) 2000-12-28
WO2000078343A8 (en) 2001-10-04
AU5885700A (en) 2001-01-09
KR20020020748A (ko) 2002-03-15
WO2000078343A3 (en) 2001-07-05
BR0011908A (pt) 2002-05-21
JP2003502384A (ja) 2003-01-21
EP1189633A2 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
Carman et al. Vaccine-induced escape mutant of hepatitis B virus
Ranger-Rogez et al. Hepatitis B mother-to-child transmission
World Health Organization Hepatitis B vaccines
CN116693666B (zh) 一种抗乙型肝炎核心抗原的单克隆抗体及其应用
CN1057774C (zh) 乙型肝炎疫苗
JP2013151496A (ja) 抗ウイルス性のヌクレオシド剤に耐性を示すｂ型肝炎ウイルスのバリアントおよびその応用法
Rivkina et al. Chronic hepatitis B: current and future treatment options
CN101309931B (zh) 包含截短的hbc核心蛋白和基于皂苷的佐剂的疫苗
Kaplan et al. Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics
Zuckerman et al. Recombinant hepatitis B triple antigen vaccine: Hepacare®
CN1365286A (zh) 治疗慢性乙型肝炎病毒感染的方法
CN107693788B (zh) 一种用于预防或治疗乙型肝炎的药物组合物及其用途
Sanyal et al. A review of multiple approaches towards an improved hepatitis B vaccine
Vyas et al. Hepatitis B virus infection—current concepts of chronicity and immunity
JP4898434B2 (ja) Ｂ型肝炎ウィルスの新規の表面タンパク質（ＨＢｓＡｇ）変異体
CN100335637C (zh) 采用丙型肝炎病毒非结构蛋白进行的基因免疫
Prince Prevention of liver cancer and cirrhosis by vaccines
JP2022513001A (ja) Ｂ型肝炎の治療のための免疫原性組成物
CN116804053B (zh) 一种抗HBcAg单克隆抗体及其应用
Chetana Quantitative Evaluation of Antibody to Hepatitis B Surface Antigen in Vaccinated Dental Health Care Workers”–a Cross Sectional Study
Beasley Hepatitis B: immunization strategies
WO2008031878A1 (en) A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
JPH11501204A (ja) 肝炎ウィルスワクチン
Lee et al. Vaccines for prevention of viral hepatitis
Hochman et al. Acute and chronic viral hepatitis

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication